3.63
4.29%
+0.13
Eton Pharmaceuticals Inc stock is currently priced at $3.63, with a 24-hour trading volume of 16,821.
It has seen a +4.29% increased in the last 24 hours and a -2.67% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.55 pivot point. If it approaches the $3.65 resistance level, significant changes may occur.
Previous Close:
$3.50
Open:
$3.52
24h Volume:
16,821
Market Cap:
$92.73M
Revenue:
$32.83M
Net Income/Loss:
$2.23M
P/E Ratio:
-15.12
EPS:
-0.24
Net Cash Flow:
$9.27M
1W Performance:
+13.71%
1M Performance:
-2.67%
6M Performance:
-14.32%
1Y Performance:
+5.19%
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
847-787-7361
Address
21925 West Field Parkway, Suite 235, Deer Park, IL
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-14-21 | Resumed | B. Riley Securities | Buy |
Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
Sep-20-19 | Initiated | B. Riley FBR | Buy |
Jun-10-19 | Initiated | H.C. Wainwright | Buy |
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
GlobeNewswire Inc.
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
GlobeNewswire Inc.
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
GlobeNewswire Inc.
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Eton Pharmaceuticals Inc (ETON) Revenue 2024
ETON reported a revenue (TTM) of $32.83 million for the quarter ending September 30, 2023, a +74.19% rise year-over-year.
Eton Pharmaceuticals Inc (ETON) Net Income 2024
ETON net income (TTM) was $2.23 million for the quarter ending September 30, 2023, a +125.10% increase year-over-year.
Eton Pharmaceuticals Inc (ETON) Cash Flow 2024
ETON recorded a free cash flow (TTM) of $9.27 million for the quarter ending September 30, 2023, a +201.11% increase year-over-year.
Eton Pharmaceuticals Inc (ETON) Earnings per Share 2024
ETON earnings per share (TTM) was $0.10 for the quarter ending September 30, 2023, a +121.28% growth year-over-year.
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company is developing DS-300, an injectable nutrition product candidate; EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-103, an oral liquid product candidate; DS-100, an injectable product candidate for use in pain management; DS-200, an injectable parenteral nutrition product candidate; ET-101, an oral liquid product for use in seizure control; ET-102, an oral liquid product for use as a muscle relaxant; and CT-100, a synthetic corticotropin therapeutic candidate that mimics the amino acid chain of H.P. Acthar Gel. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Cap:
|
Volume (24h):